About Express Scripts (NASDAQ:ESRX)
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900
Debt
Debt-to-Equity Ratio0.81
Current Ratio0.69
Quick Ratio0.56
Price-To-Earnings
Trailing P/E Ratio11.34
Forward P/E Ratio8.87
P/E Growth1.03
Sales & Book Value
Annual Sales$100.06 billion
Price / Sales0.45
Cash Flow$10.3312 per share
Price / Cash7.79
Book Value$32.00 per share
Price / Book2.52
Profitability
EPS (Most Recent Fiscal Year)$7.10
Net Income$4.52 billion
Net Margins4.59%
Return on Equity25.41%
Return on Assets8.28%
Miscellaneous
Employees26,600
Outstanding Shares561,720,000
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How will Express Scripts' stock buyback program work?
Express Scripts announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, December 20th 2017, which authorizes the company to repurchase 45,000,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's management believes its shares are undervalued.
How were Express Scripts' earnings last quarter?
Express Scripts Holding Co (NASDAQ:ESRX) issued its earnings results on Wednesday, May, 2nd. The company reported $1.77 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.76 by $0.01. The business had revenue of $24.77 billion for the quarter, compared to analysts' expectations of $24.80 billion. Express Scripts had a return on equity of 25.41% and a net margin of 4.59%. The business's revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $1.33 EPS. View Express Scripts' Earnings History.
When is Express Scripts' next earnings date?
What guidance has Express Scripts issued on next quarter's earnings?
Express Scripts issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $9.00-9.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.33.
What price target have analysts set for ESRX?
18 Wall Street analysts have issued 12-month target prices for Express Scripts' stock. Their predictions range from $57.00 to $101.00. On average, they expect Express Scripts' stock price to reach $82.3462 in the next year. View Analyst Ratings for Express Scripts.
What are Wall Street analysts saying about Express Scripts stock?
Here are some recent quotes from research analysts about Express Scripts stock:
- 1. According to Zacks Investment Research, "Express Scripts recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. Moreover, the company faces stiff competition, which raises concern. The company recently announced that it is getting acquired by Cigna Corporation, a global health insurance company. However, it has been benefitting from a rise in patient claims and strong customer retention. Express Scripts’ solid guidance for 2018 holds promise. Express Scripts' pharmacy-benefit management segment (PBM) coupled with recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. In the past six months, Express Scripts has outperformed the industry in terms of price." (5/1/2018)
- 2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)
Are investors shorting Express Scripts?
Express Scripts saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 14,969,888 shares, an increase of 15.3% from the May 15th total of 12,982,101 shares. Based on an average daily volume of 3,248,116 shares, the days-to-cover ratio is currently 4.6 days. Currently, 2.7% of the shares of the stock are short sold.
Who are some of Express Scripts' key competitors?
Who are Express Scripts' key executives?
Express Scripts' management team includes the folowing people:
- Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
- Mr. James M. Havel, Exec. VP & CFO (Age 63)
- Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
- Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
- Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)
Has Express Scripts been receiving favorable news coverage?
Press coverage about ESRX stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Express Scripts earned a media sentiment score of 0.05 on Accern's scale. They also assigned press coverage about the company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Express Scripts' major shareholders?
Express Scripts' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.21%), Barrow Hanley Mewhinney & Strauss LLC (2.56%), Northern Trust Corp (1.81%), Massachusetts Financial Services Co. MA (1.28%), Dimensional Fund Advisors LP (1.15%) and LSV Asset Management (0.91%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Which institutional investors are selling Express Scripts stock?
ESRX stock was sold by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Barrow Hanley Mewhinney & Strauss LLC, OppenheimerFunds Inc., Manning & Napier Group LLC, BlackRock Inc., Schwab Charles Investment Management Inc., Pzena Investment Management LLC and Schroder Investment Management Group. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.
Which institutional investors are buying Express Scripts stock?
ESRX stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, State of New Jersey Common Pension Fund D, Smith Asset Management Group LP, O Shaughnessy Asset Management LLC, Mackay Shields LLC, Massachusetts Financial Services Co. MA, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Express Scripts.
How do I buy shares of Express Scripts?
Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of ESRX stock can currently be purchased for approximately $80.48.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $45.92 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (ESRX)
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
